Employers are required to make an assessment of the health risk created by such work, and to prevent or control exposure to the substances involved.
3 Exposure to hydroquinone can cause skin irritation and sensitisation, and irritation to the eyes, nose and throat.2 Hydroquinone has also been shown to be mutagenic in animals and a no-adverse-effect-level cannot be identified in humans.
100 Asbestos-containing materials © Crown copyright 2003 Applications for reproduction should be made in writing to: Copyright Unit, Her Majesty's Stationery Office, St Clements House, 2-16 Colegate, Norwich NR3 1BQ All rights reserved.

http://www.hse.gov.uk/pubns/mdhs/pdfs/mdhs98.pdf
No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording or otherwise) without the prior written permission of the copyright owner. measurements, water.

reg2083

http://www.doh.gov.za/docs/regulations/1983/reg2083.pdf
2. (1) Subject to the provisions of subregulation (2), no person, shall sell (a) a cosmetic which contains lead or its salts, hydroquinone monobenzyl ether (p-hydroxyphenyl benzyl ether or monobenzone), or mercury or its salts; or (b) a cosmetic as a skin lightening agent or skin whitener, or a cosmetic purporting to be a skin lightening agent or skin whitener, which (i) contains any active or petentially depigmenting ingredient other than hydroquinone; (ii) contains more than 2 per cent hydroquinone by volume or mass, whichever is the greater in a specific preparation; (iii) contains catechols, salicylic acid, methyl salicylate, trimethyl cyclohexanol, resorcinol, oxyquinoline, sulphate, odochlorohydroxyquin, thymol, hexachlorophene and other phenolic compounds; (iv) does not contain a sun screen with a protection factor (SPF) of 5 or an equivalent sun blocking agent in the finished product; or (c) any cosmetic which contains hydroquinone other than a cosmetic referred to in paragraph (b); or (d) any cosmetic designated as "Blue Butter", "Blue Ointment" or "Blou Botter". cosmetics, salicylate.

5004

OTHER METHODS: This is Method S57 [2] in a revised format.
The equilibrium vapor pressure is equivalent to 0.11 mg/m 3 at 25 °C and may be a significant factor at elevated temperatures.
Immediately after sampling, transfer the filter (do not include backup pad) with tweezers to a 60-mL ointment jar.
Check recovery with at least three spiked media blanks per sample set.
The atmospheres were generated by atomization of an aqueous solution of hydroquinone into dry air; aerosol concentrations were independently verified by direct UV spectrophotometry on filter samples.

http://www.cdc.gov/niosh/nmam/pdfs/5004.pdf
Average collection efficiency was 100% at 4 mg/m loss of hydroquinone was seen from filters spiked with 720 µg hydroquinone, and then used to sample 180 L clean air, indicating the hydroquinone vapor pressure is not significant at these conditions. hydroquinone, recovery.

03p-0365-pdn00002-vol1.pdf

Your petition was filed on August 13,2003 and requested permission to file an Abbreviated New Drug Application (ANDA) for the following drug product: Hydroquinone and Tretinoin Topical Solution, 4%/0.01%.
Your request involves a change from one active ingredient to another active ingredient in the same pharmacologic or therapeutic class from that of the listed combination drug product (i.e., to Hydroquinone 4%).
The Agency has determined that your proposed change in active ingredient raises questions of safety and effectiveness, and has concluded that clinical trials are required for these specific drug products.

http://www.fda.gov/ohrms/dockets/dockets/03p0365/03p-0365-pdn00002-vol1.pdf
If there is additional information, not included as part of your original submission that you would like the Agency to consider, you should submit a new petition including all the necessary information to the Dockets Management Branch. drug product, proposed drug products.